2010-08-12-Bain-Changing_pharma_s_innovation_DNA_12页_724kb

Pharmaceutical R&D is facing a crisis due to declining productivity, high costs (e.g., over $2 billion per drug), and a widening profit gap, exacerbated by patent expirations and generic competition.

Key issues include risk aversion, misaligned incentives, lack of managerial autonomy, and slow decision-making, hindering breakthrough innovations.

A radical transformation is needed, focusing on medical differentiation, flexible organization structures, and minimizing bureaucracy to foster innovation.

Bain's framework suggests an "Innovation Centers" (IC) model: disease-area focused teams with high autonomy, external collaboration, and portfolio-based resource allocation to prioritize high-impact projects.

For successful implementation, companies must shift incentives to reward innovation outcomes, increase managerial freedom, attract top talent, and establish functional flexibility through outsourcing and virtual teams.

This change requires leadership to balance scale and creativity, engage stakeholders like payers, and adopt a venture-capital-like approach to innovation investments.

• Leaders should define unmet medical needs and innovations that justify competitive pricing.

Challenges involve stakeholder engagement and cultural shifts, with potential benefits including efficient late-stage development and collaborative models, but transformation is slow and demands bold direction.